Phase 2 Readouts — Q1 2027
Phase 2 trials test drug efficacy in 100-300 patients with the target condition. Positive Phase 2 data validates the drug mechanism and sets the stage for pivotal Phase 3 trials.
6 phase 2 readouts in Q1 2027. Updated .
Phase 2 Readout: alstars
Coya Therapeutics, Inc. (COYA)
Phase 2 Readout: com701
COMPUGEN LTD (CGEN)
Phase 2 Readout: maia
COMPUGEN LTD (CGEN)
Phase 2 Readout: volixibat
Mirum Pharmaceuticals, Inc. (MIRM)
Phase 2 Readout: enobosarm + semaglutide
VERU INC. (VERU)
Phase 2 Readout: cr-001
CRESCENT BIOPHARMA, INC. (CBIO)